The Food and Drug Administration (FDA) has reported a shortage of Etopophos (etoposide phosphate; Bristol-Myers Squibb) Injection as of September 16, 2016.

Etopophos Injection is currently on backorder due to a shortage of the active ingredient. It is a topoisomerase inhibitor indicated for refractory testicular tumors after appropriate radiation, surgery, and other chemotherapy; and for the treatment of small cell lung cancer. 

Related Articles

The in vitro cytotoxicity observed for etoposide phosphate is significantly less than that seen with etoposide which is believed to be due to the necessity for conversion in vivo to the active moiety, etoposide, by dephosphorylation. The mechanism of action is believed to be the same as that of etoposide. The predominant effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA topoisomerase II or the formation of free radicals.

Etopophos was supplied as 100mg powder per vial for IV infusion after reconstitution and dilution. The Company is working to resolve the backorder as soon as possible. Etopophos Injection is estimated to be available again in September 2017.

For more information call (800) 332-2056 or visit